Jonathan Schwartz, M.D., appointed Chief Gene Therapy Officer to enhance the Company’s focus on strategic application of gene therapy technologies to current and future therapeutic areasMark White, MB.ChB, named Chief Medical Officer; Dr. White brings proven track record in late-stage development and commercializati.
CRANBURY, N.J. (BUSINESS WIRE) Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to part.
Rocket Pharmaceuticals (RCKT) Adds RP-A601 to Cardiac Gene Therapy Portfolio, Reports Positive Updated Phase 1 Data for RP-A501 in Danon Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Acquisition further extends Rocket’s leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathyCRANBURY, N.J. (BUSINESS WIRE) Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainabl.
Rocket Pharmaceuticals Completes Acquisition of Renovacor streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.